Topline results from the phase 3 THALES trial show that in patients who had experienced an acute ischemic stroke or transient ischemic attack (TIA), the antiplatelet agent ticagrelor (Brilinta, AstraZeneca), in combination with aspirin, demonstrated a statistically significant reduction in the rate of repeat stroke or death compared to placebo.
A study by researchers at Ohio State University and the Lawrence Berkeley National Laboratory has found a large number of ancient viruses in ice core samples collected from a glacier on the Tibetan plateau that were approximately 15,000 years old.
Herpesviruses have been isolated from a wide range of hosts including humans-for which, nine species have been designated. The human herpesviruses are highly host adapted and possess the capacity for latency, allowing them to survive in the host for life, effectively hidden from the immune system. This ability of human herpesviruses to modulate the...
Misfolded alpha-synuclein proteins in the brain are the hallmark sign of Parkinson's disease.
Stroke and sleep apnea are highly prevalent conditions with a physiologically plausible bidirectional relationship.
Visual snow is considered a disorder of central visual processing resulting in a perturbed perception of constant bilateral whole-visual field flickering or pixelation. When associated with additional visual symptoms, it is referred to as visual snow syndrome. Its pathophysiology remains elusive.
To help determine whether midlife obesity is a cause of dementia and whether low body mass index (BMI), low caloric intake, and physical inactivity are causes or merely consequences of the gradual onset of dementia by recording these factors early in a large 20-year prospective study and relating them to dementia detection rates separately during...
Second language learning induces grey matter volume increase in people with multiple sclerosis.
A recent study shows that healthy sleep patterns were associated with a reduced risk of heart disease and stroke by about one-third, even among those at high genetic risk.
Ubrogepant is the first drug in the calcitonin-related peptide receptor antagonist class approved for the acute treatment of migraine.
